KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Short-term Investments (2020 - 2025)

Historic Short-term Investments for Royalty Pharma (RPRX) over the last 6 years, with Q4 2025 value amounting to $18.8 million.

  • Royalty Pharma's Short-term Investments fell 6769.76% to $18.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $18.8 million, marking a year-over-year decrease of 6769.76%. This contributed to the annual value of $18.8 million for FY2025, which is 6769.76% down from last year.
  • Latest data reveals that Royalty Pharma reported Short-term Investments of $18.8 million as of Q4 2025, which was down 6769.76% from $16.1 million recorded in Q3 2025.
  • Over the past 5 years, Royalty Pharma's Short-term Investments peaked at $409.3 million during Q3 2022, and registered a low of $1.3 million during Q4 2022.
  • Moreover, its 5-year median value for Short-term Investments was $33.8 million (2024), whereas its average is $68.8 million.
  • Over the last 5 years, Royalty Pharma's Short-term Investments had its largest YoY gain of 130769.23% in 2023, and its largest YoY loss of 9870.53% in 2023.
  • Royalty Pharma's Short-term Investments (Quarter) stood at $66.0 million in 2021, then crashed by 98.03% to $1.3 million in 2022, then surged by 1307.69% to $18.3 million in 2023, then soared by 218.03% to $58.2 million in 2024, then crashed by 67.7% to $18.8 million in 2025.
  • Its Short-term Investments was $18.8 million in Q4 2025, compared to $16.1 million in Q3 2025 and $13.2 million in Q2 2025.